2020

News
Share this article
24 January 2020

Phenotypic Screening now offered by the European Lead Factory

Phenotypic Screening is a powerful target-agnostic approach to identifying new chemical starting points for drug discovery. Furthermore, it offers the potential to uncover new targets and pathways underpinning disease-related biology.

News
Share this article
24 January 2020

Collaboration breeds success: Discovery of a new chemical class to investigate role of EPAC proteins in diabetes and cardiovascular diseases

Scientists from the Yarwood Lab and the European Screening Centre have jointly published on the discovery of a new class of EPAC activators. The study, which describes the identification, optimisation and characterisation of a new chemical class of selective agonists for EPAC1, is the result of another successful collaboration within the framework of the European Lead Factory (ELF).

News
Share this article
15 January 2020

Our Compound Collection shipped to participating screening centres all over Europe

The European Lead Factory (ELF) project has some impressive numbers to share! Over the past months, ELF Partner BioAscent has shipped 3,256 screening plates from the updated Compound Collection to the nine screening sites that are part of ELF.

News
Share this article
13 January 2020

The European Lead Factory supports World Neglected Tropical Diseases Day

This 30 January marks the inaugural World Neglected Tropical Diseases (NTD) Day, an initiative designed to draw attention to priority issues surrounding NTDs and the efforts being made to combat them. Falling on the anniversary of the landmark 2012 London Declaration on NTDs, which united partners in the drive for greater action on NTDs, the Day hopes to inspire further support for this cause.

News
Share this article
13 January 2020

Significant steps taken in the development of potential new cancer treatments

Together with the European Lead Factory (ELF), scientists from the German Cancer Research Center (DKFZ) have successfully discovered potent and selective inhibitors of enzymes associated with the development of some cancers and neurodegenerative diseases. Published in ChemMedChem, the findings mark a significant step in the development of potential new cancer treatments.